Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $14.53B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 ·
Decision snapshot: RVTY stock price vs VNDA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VNDA's multiple
Needs VNDA P/E.
Implied fair value · at RVTY's multiple
Needs EPS (TTM) is negative, RVTY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RVTY FY 2025 (ended Dec 28, 2025) · VNDA FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 82% equity / 18% debt · EV / Revenue 5.89x · EV / EBITDA 22.11x
Capital structure 81% equity / 19% debt · EV / Revenue 1.49x
RVTY carries the larger enterprise value at $16.83B against $321.69M; VNDA trades on the lower EV / Revenue multiple (1.49x vs 5.89x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
REVVITY, INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
VANDA PHARMACEUTICALS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.44x
0.24x
Net debt / EBITDA
Leverage against operating earnings
3.02x
0.05x
Cash and equivalents
Liquid reserves on the balance sheet
$919.86M
$84.85M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AGILENT TECHNOLOGIES, INC.
RVTY vs A
WATERS CORP /DE/
RVTY vs WAT
BIO-RAD LABORATORIES, INC.
RVTY vs BIO
METTLER TOLEDO INTERNATIONAL INC/
RVTY vs MTD
DANAHER CORP /DE/
RVTY vs DHR
THERMO FISHER SCIENTIFIC INC.
RVTY vs TMO
SUPERNUS PHARMACEUTICALS, INC.
RVTY vs SUPN
CATALYST PHARMACEUTICALS, INC.
RVTY vs CPRX
Harmony Biosciences Holdings, Inc.
RVTY vs HRMY
ELI LILLY & Co
RVTY vs LLY
INCYTE CORP
RVTY vs INCY
Sarepta Therapeutics, Inc.
RVTY vs SRPT
$3.22B
$78.23M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
